Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

Also called NCT01159249

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01159249
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01159249. Non-randomized; no masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
Intervention (Drug)
Vildagliptin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01159249
Content hash
c6c6303e46cae61088b41cf10c01c5b4daba4aaa3fe92823e59bd2812817e99b